Endocrines,
Год журнала:
2024,
Номер
5(4), С. 465 - 477
Опубликована: Окт. 5, 2024
Background:
T1D
is
a
severe
metabolic
disorder
due
to
selective
autoimmune
pancreatic
islet
β-cell
killing,
which
results
in
complete
abrogation
of
endogenous
insulin
secretion.
The
affected
patients,
once
the
disease
clinically
overt,
must
immediately
undertake
supplementation
according
intensive
therapy
regimens
prevent
onset
acute
and
chronic
complications,
some
them
potentially
lethal.
Replacement
destroyed
β-cells
with
fresh
vital
endocrine
tissue,
either
whole
organ
or
isolated
islets
transplantation,
started
few
decades
ago
progressively
encouraging
results,
although
exogenous
withdrawal
was
obtained
minor
cohort
treated
patients.
restricted
availability
donor
organs
coupled
general
immunosuppression
treatment
recipients
avoid
graft
immune
rejection
may,
at
least
partially,
explain
limited
success
achieved
by
these
procedures.
Results:
introduction
pluripotent
stem
cells
(either
human
embryonic
origin
adult
genetically
induced
pluripotency)
that
can
be
differentiated
toward
secretory
β-like
could
provide
an
indefinite
resource
for
insulin-producing
(IPCs).
Conclusions:
Because
use
embryos
may
encounter
ethical
problems,
employment
multipotent
mesenchymal
(MSCs)
extracted
from
several
tissues
represent
alternative
option.
MSCs
are
associated
strong
immunoregulatory
properties
alter
early
stages
β-cell-directed
autoimmunity
T1D,
other
than
holding
potential
differentiate
themselves
into
cells.
Lights
shadows
new
strategies
cure
their
advancement
state
reviewed.
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(7), С. 2144 - 2144
Опубликована: Март 21, 2025
Background:
Type
1
diabetes
(T1D)
is
a
chronic
autoimmune
disorder
characterized
by
the
destruction
of
pancreatic
β-cells,
leading
to
absolute
insulin
deficiency.
Despite
advancements
in
therapy
and
glucose
monitoring,
achieving
optimal
glycemic
control
remains
challenge.
Emerging
technologies
novel
therapeutic
strategies
are
transforming
landscape
T1D
management,
offering
new
opportunities
for
improved
outcomes.
Methods:
This
review
synthesizes
recent
treatment,
focusing
on
innovations
continuous
monitoring
(CGM),
automated
delivery
systems,
smart
formulations,
telemedicine,
artificial
intelligence
(AI).
Additionally,
we
explore
biomedical
approaches
such
as
stem
cell
therapy,
gene
editing,
immunotherapy,
gut
microbiota
modulation,
nanomedicine-based
interventions,
trace
element-based
therapies.
Results:
Advances
digital
health,
including
CGM
integration
with
hybrid
closed-loop
pumps
AI-driven
predictive
analytics,
have
significantly
real-time
management.
AI
telemedicine
enhanced
personalized
care
patient
engagement.
Furthermore,
regenerative
medicine
strategies,
β-cell
replacement,
CRISPR-based
immunomodulatory
therapies,
hold
potential
disease
modification.
Probiotics
microbiome-targeted
therapies
demonstrated
promising
effects
maintaining
metabolic
homeostasis,
while
elements
provide
additional
regulate
sensitivity
oxidative
stress.
Conclusions:
The
future
management
shifting
toward
precision
integrated
technological
solutions.
While
these
present
avenues,
challenges
long-term
efficacy,
safety,
accessibility,
clinical
validation
must
be
addressed.
A
multidisciplinary
approach,
combining
research,
intelligence,
nanotechnology,
will
essential
translate
into
practice,
ultimately
improving
quality
life
individuals
T1D.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(10), С. 5292 - 5292
Опубликована: Май 13, 2024
Harnessing
of
CRISPR/Cas
(Clustered
Regularly
Interspaced
Short
Palindromic
Repeats/CRISPR-associated
genes)
systems
for
detection,
chemical
modification,
and
sequence
editing
nucleic
acids
dramatically
changed
many
fields
fundamental
science,
biotechnology,
biomedicine
[...]
Theoretical and Natural Science,
Год журнала:
2025,
Номер
82(1), С. 19 - 26
Опубликована: Янв. 15, 2025
Diabetes
is
a
chronic
disease
with
rapid
increase
in
incidence,
which
general
problem
around
the
world.
Two
main
types
of
diabetes
are
included.
Polygenic
includes
type
1
(T1D)
and
2
(T2D),
their
monogenic
forms
juvenile
mature
(MODY)
neonatal
(NDM).
CRISPR
technology
gene
therapy
low
cost
but
very
high
feasibility.
At
present,
researchers
have
envisioned
use
treatment
T1D,
this
has
off-target
rate,
immune
rejection
no
abundant
clinical
trials
human
body
to
verify
technology,
resulting
fact
that
not
really
used
treatment.
In
middle.
This
article
mainly
analyzes
summarizes
problems
solutions
encountered
by
CRISPR-cas9
from
basic
theory
idealized
models.
provides
new
for
T1D
also
references
technology.
addition,
such
as
been
solved.
Future
research
can
focus
on
solution
suppression
cellular
after
impact
re-mutation.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(24), С. 13321 - 13321
Опубликована: Дек. 12, 2024
CRISPR–Cas
technology
has
transformed
the
field
of
gene
editing,
opening
new
possibilities
for
treatment
various
genetic
disorders.
Recent
years
have
seen
a
surge
in
clinical
trials
using
CRISPR–Cas-based
therapies.
This
review
examines
current
landscape
implementation
trials,
with
data
from
key
registries,
including
Australian
New
Zealand
Clinical
Trials
Registry,
Chinese
Trial
Register,
and
ClinicalTrials.gov.
Emphasis
is
placed
on
mechanism
action
tested
therapies,
delivery
method,
most
recent
findings
each
trial.
Frontiers in Genome Editing,
Год журнала:
2024,
Номер
6
Опубликована: Дек. 12, 2024
CRISPR-Cas
(Clustered
Regularly
Interspaced
Short
Palindromic
Repeats-CRISPR-associated
proteins)
has
undergone
marked
advancements
since
its
discovery
as
an
adaptive
immune
system
in
bacteria
and
archaea,
emerged
a
potent
gene-editing
tool
after
the
successful
engineering
of
synthetic
guide
RNA
(sgRNA)
toward
targeting
specific
DNA
sequences
with
high
accuracy.
Besides
editing
ability,
further-developed
Cas
variants
can
also
edit
epigenome,
rendering
versatile
for
genome
epigenome
manipulation
pioneering
force
precision
medicine.
This
review
explores
latest
technology
therapeutic
biomedical
applications,
highlighting
transformative
impact
on
Moreover,
current
status
CRISPR
therapeutics
clinical
trials
is
discussed.
Finally,
we
address
persisting
challenges
prospects
technology.
International Journal of Research in Medical Sciences,
Год журнала:
2024,
Номер
12(6), С. 2200 - 2211
Опубликована: Май 31, 2024
CRISPR/Cas9
mediated
genome
editing
is
one
of
the
most
significant
molecular
tools
discovered
to
edit
desired
genes.
It
has
ushered
in
a
new
era
novel
possibilities
gene
therapy.
system
was
originally
observed
as
part
adaptive
immune
bacteria.
later
on
adapted
carry
precise
and
targeted
alterations
DNA
human
cells
be
used
for
therapy
correct
genetic
disorders
treat
various
severe
diseases
associated
with
changes.
Besides
this,
been
employed
pharmacogenomics
develop
drugs
based
patient’s
genes,
modifying
organisms
research
even
diagnostic
purposes
developing
CRISPR
COVID-9
test.
The
recent
approval
cellular
by
FDA
named
“Casgevy”
sickle
cell
anemia
testimonial
potentials
innovative
therapies.
This
review
details
mechanisms
its
utilization
ongoing
clinical
trials
treatment
not
only
monogenic
like
disease,
thalassemia,
blindness
but
also
treating
multi-factorial
cancers,
cardiac
diseases,
diabetes,
autoimmune
viral
infections
such
immunodeficiency
virus
(HIV)
etc.
An
attempt
made
discuss
limitations,
challenges
ethical
frameworks
encompassing
settings.
Adequate
and
timely
glucose
level
assessment
is
of
utmost
importance
for
persons
with
diabetes
when
aiming
optimal
glycemic
control
thus
avoid
or
delay
the
development
micro-
macrovascular
complications.
In
this
thesis,
effects
Flash
Glucose
Monitoring
(FGM)
on
well-being
in
are
explored.
FGM
a
form
continuous
monitoring
that
requires
scanning
sensor
to
obtain
information
aboutthe
concentration
interstitial
fluid.
contrast
fingerprick
(point)
measurements,
more
convenient,
provides
insight
fluctuations
trends
during
day
night,
allows
frequent
assessment.
Previous
studies
had
limited
follow-up
period
were
mainly
focused
change
HbA1c
as
outcome
parameter.
first
part
longer-term
effectiveness
who
started
was
assessed.
continued
use
two
years,
sustained
improvement
quality
life
observed.
Commencement
also
associated
mental
well-being.
A
higher
baseline
correlated
greater
decline
HbA1c.The
second
thesis
into
changes
parameters
different
levels
(dys)regulation.
Initiation
parameters,
irrespective
pre-use
regulation
treatment
modality.
flash
scan
rate
control,
e.g.
time
target
range,
hyperglycemia
variability.
